|
1
|
Sun YH, Zhang XY, Xie WQ, Liu GJ, He XX,
Huang YL, Zhang GX, Wang J, Kuang ZY and Zhang R: Identification of
UQCRB as an oxymatrine recognizing protein using a T7 phage display
screen. J Ethnopharmacol. 193:133–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang YB, Zhan LQ, Li GQ, Wang F, Wang Y,
Li YL, Ye WC and Wang GC: Dimeric matrine-type alkaloids from the
roots of Sophora flavescens and their anti-hepatitis B virus
activities. J Org Chem. 81:6273–6280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen JX, Shen HH, Niu M, Guo YM, Liu XQ,
Han YZ, Zhang YM, Zhao YL, Bai BK, Zhou WJ, et al: Anti-hepatitis B
virus effect of matrine-type alkaloid and involvement of p38
mitogen-activated protein kinase and tumor necrosis factor
receptor-associated factor 6. Virus Res. 215:104–113. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kan QC, Zhang S, Xu YM, Zhang GX and Zhu
L: Matrine regulates glutamate-related excitotoxic factors in
experimental autoimmune encephalomyelitis. Neurosci Lett.
560:92–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma ZJ, Li Q, Wang JB, Zhao YL, Zhong YW,
Bai YF, Wang RL, Li JY, Yang HY, Zeng LN, et al: Combining
oxymatrine or matrine with lamivudine increased its antireplication
effect against the hepatitis B virus in vitro. Evid Based
Complement Alternat Med. 2013:1865732013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen CX, Liu B, Hu Y, Johnson JE and Tang
YW: Subacute fulminant hepatic failure with intermittent fever.
Hepatobiliary Pancreat Dis Int. 8:657–659. 2019.2009.
|
|
7
|
Chen CX, Liu B, Ma Y, Zhou YJ, Pan XN,
Zhen RD, Wang QC, Wang MR, He CL, Fu QC, et al: Lamivudine,
interferon-alpha and oxymatrine treatment for the surviving hepatic
failure patients with hepatitis B. Zhonghua Gan Zang Bing Za Zhi.
17:505–508. 2009.(In Chinese). PubMed/NCBI
|
|
8
|
Ye G, Zhu HY, Li ZX, Ma CH, Fan MS, Sun ZL
and Huang CG: LC-MS characterization of efficacy substances in
serum of experimental animals treated with Sophora flavescens
extracts. Biomed Chromatogr. 21:655–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Y, Pan F, Wang Y, Chen Z, Lin C, Yao
L, Zhang X, Zhou R and Pan C: Adefovir dipivoxil-induced Fanconi
syndrome and its predictive factors: A study of 28 cases. Oncol
Lett. 13:307–314. 2017.PubMed/NCBI
|
|
10
|
Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang
QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, et al: On-treatment
quantitative hepatitis B e antigen predicted response to
nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol.
8:1511–1520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo Q, Deng Y, Cheng F, Kang J, Zhong S,
Zhang D and Zeng W: Relationship between nephrotoxicity and
long-term adefovir dipivoxil therapy for chronic hepatitis B: A
meta-analysis. Medicine (Baltimore). 95:e55782016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen X, Fu B, Liu Y, Guo C, Ye Y, Sun R,
Li J, Tian Z and Wei H: NKp30(+) NK cells are associated with HBV
control during pegylated-interferon-alpha-2b therapy of chronic
hepatitis B. Sci Rep. 6:387782016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang LP, Han FZ, Yan XB, Fan YC and Wang
K: Relationship between hepatitis B virus reverse transcriptase 181
mutation and S gene mutation in hepatitis B virus chronically
infected patients. Cell Mol Biol (Noisy-le-grand). 62:18–23.
2016.PubMed/NCBI
|
|
14
|
Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP,
Gong WF, You XM, Ma L, Xiang BD and Li LQ: Adefovir dipivoxil is
less expensive than lamivudine and associated with similar
prognosis in patients with hepatitis B virus-related hepatocellular
carcinoma after radical resection. Onco Targets Ther. 9:6897–6907.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Shen C, Wang Y, Wang W, Zhao Q, Liu
Z, Wang Y and Zhao C: Circulating kidney injury molecule-1 is a
novel diagnostic biomarker for renal dysfunction during long-term
adefovir therapy in chronic hepatitis B. Medicine (Baltimore).
95:e52642016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hara Y, Tokodai K, Nakanishi C, Miyagi S
and Kawagishi N: Spontaneous resolution of de novo hepatitis B
after living donor liver transplantation with hepatitis B core
antibody positive graft: A case report. Surg Case Rep. 2:1182016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Banerjee S, Gunda P, Drake RF and Hamed K:
Telbivudine for the treatment of chronic hepatitis B in
HBeAg-positive patients in China: A health economic analysis.
Springerplus. 5:17192016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tacke F and Kroy DC: Treatment for
hepatitis B in patients with drug resistance. Ann Transl Med.
4:3342016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang
H, Lin T, Jiang W, Xia Z, Duan H, et al: The effect of prophylactic
lamivudine plus adefovir therapy compared with lamivudine alone in
preventing hepatitis B reactivation in lymphoma patients with high
baseline HBV DNA during chemotherapy. PLoS One. 11:e01642102016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawamura Y, Kobayashi M, Saitoh S, Arase
Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Suzuki F, Suzuki Y, et
al: Efficacy of long-term tenofovir-based rescue therapy in
patients with chronic hepatitis B refractory to
nucleoside/nucleotide analogs. J Gastroenterol. 11:132–136.
2016.
|
